Head-to-head · WeighScore
Fierce Health vs HealthSource
The verdict
HealthSource takes it — 71.2/100 to 56.6/100.
HealthSource grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. HealthSource is a telehealth weight-management platform offering compounded semaglutide and tirzepatide (injectable and oral sublingual) dispensed through a US-based FDA 503A licensed partner pharmacy.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Fierce Health | HealthSource |
|---|---|---|
| WeighScore | 56.6/100 | 71.2/100 |
| Grade | C | C |
| Scorecard rank | #411 | #97 |
| Semaglutide | $297/mo (3-month plan, compounded) | $199/mo (all doses, compounded) |
| Tirzepatide | $497/mo (3-month plan, compounded) | $299/mo (all doses, compounded) |
| Coverage | 30 states | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #411 · C
Strengths
- 30-state service list spelled out in the Terms — buyers can verify eligibility before intake
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer on every product page
- Four GLP-1 programs (standard and microdose semaglutide and tirzepatide) — a broader ladder than peers
- Microdose tier at $197/mo is one of the lower entry points we've seen
Where it loses points
- No named 503A compounding pharmacy partner — only generic 'partner pharmacies' language
- Operating LLC name not disclosed anywhere on the site
- Tirzepatide weight-loss program ($497/mo) showing 'sold out or unavailable' across all plans at review time
- Clinical provider network not named
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #97 · C
Strengths
- Three GLP-1 options: compounded semaglutide injection, tirzepatide injection, and oral sublingual tirzepatide
- 24/7 access to care team via HIPAA-compliant platform with unlimited physician messaging
- Every program covers the cost of medication, supplies, and telehealth visits — no separate pharmacy fee
- Subscription auto-refund if monthly reassessment is not completed
- Available in all 50 US states including Alaska and Hawaii with 3–5 day shipping
Where it loses points
- No physician names or clinical leadership disclosed on public pages
- No LegitScript certification found
- 503A partner pharmacy not named — less transparent than providers disclosing their 503B pharmacy
- Labs not mentioned on any product page — baseline bloodwork protocol unknown
- WooCommerce e-commerce storefront may feel more transactional than clinical
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.